The American Journal of Medicine is offering a new continuing medical education (CME) course on multiple sclerosis:
Multiple Sclerosis Updates: Disease Management and Clinical Trial Data
The 65th Annual Meeting of the American Academy of Neurology (AAN 2013) presented lectures, data, poster sessions, and panel discussions that provided up-to-date information on current clinical trials. Further insight concerning the roles of inflammation, nerve degeneration, and atrophy, as well as gray matter versus white matter, shed light on a deeper understanding of the pathophysiology of multiple sclerosis. The clinical trial data on several newer classes of therapeutics arms the neurologist with many treatment options that reduce relapses and delay progression of disease. Additionally, longer-term data gives a more lucid perspective on therapeutic safety.
This review of AAN 2013 is designed to not only bring the neurologist current on multiple sclerosis research, but also present practical applications of the science for daily clinical practice. Principles of early diagnosis, early intervention, aggressive disease management, close monitoring, and opportunities to switch therapies are supported by recent data and will guide clinical decision making to improve patient outcomes.
Target Audience
This activity was designed to meet the needs of neurologists, neuroscience professionals, neurological nurses, primary care providers, and other healthcare professionals who care for patients with multiple sclerosis.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review advances in neurosciences and pathophysiology of multiple sclerosis.
- Describe the most up-to-date clinical trial data for emerging therapies as well as longer term data on efficacy and safety of currently available therapeutics.
- Develop more current strategies and treatment plans for the management of patients with multiple sclerosis.
Follow this link for additional details or to log on to the CME module.
